New Recruiting Trial: Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
WHY IT MATTERS
This trial offers a potential new treatment option for patients with relapsed or refractory T-cell lymphoma who have limited alternatives after standard therapies fail, with enrollment beginning in April 2026.
Researchers are testing a new type of cell therapy made from umbilical cord blood to treat T-cell lymphoma that has stopped responding to other treatments. The therapy uses special immune cells called NK cells that are engineered to recognize and attack cancer cells. This is an early-stage study (Phase 1) that is now accepting patients.
NCT ID: NCT07164560 Title: Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma Status: RECRUITING Phase: PHASE1 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT07164560 Source: UniteRare clinical trials database